When chance leads to a breakthrough: serendipity in medicine

Abstract

The text analyzes the role of serendipity—accidental discoveries—in the development of medicine and pharmacology, emphasizing that many breakthrough therapies have emerged as unintended outcomes of research conducted for entirely different purposes. Drawing on numerous historical and contemporary examples—such as the discovery of penicillin, statins, tamoxifen, sildenafil, and new applications of propranolol—the author demonstrates that the key factor is not chance itself, but the ability of well-prepared researchers to interpret unexpected findings.
The theoretical section discusses the concept of serendipity in the context of the philosophy of science and the psychology of discovery, referring to the ideas of thinkers such as Popper, Kuhn, and Pasteur. It highlights that scientific discoveries are processes requiring both knowledge and openness to anomalies, as well as the ability to connect seemingly unrelated facts. The historical analysis shows that chance has played a significant role in the development of antibiotics, diagnostic imaging, vaccination, and hormonal therapies.
The contemporary section emphasizes the importance of new technologies, including Big Data analysis and artificial intelligence, which enable the identification of non-obvious correlations and accelerate the discovery process. At the same time, the author draws attention to the limitations and risks associated with excessive reliance on incidental observations, stressing the need for their verification through scientific methods and consideration of ethical aspects.
The paper concludes that chance is an important but insufficient factor in the advancement of medicine—its significance emerges only when combined with knowledge, critical thinking, and research responsibility.